Novo Nordisk A/S Logo

Novo Nordisk A/S

NVO

(4.0)
Stock Price

85,00 USD

28.64% ROA

86.4% ROE

39.48x PER

Market Cap.

3.553.257.780.749,20 USD

50.71% DER

1.22% Yield

35.01% NPM

Novo Nordisk A/S Stock Analysis

Novo Nordisk A/S Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Novo Nordisk A/S Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (86.86%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a low debt to equity ratio (29%), which means it has a small amount of debt compared to the ownership it holds

4 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

5 Net Profit Growth

The net profit of this company has steadily increased over the last five years, showcasing a favorable financial performance and making it an enticing option for investors seeking growth potential.

6 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

7 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

8 Dividend Growth

The company's dividend growth has exhibited a remarkable upward trend over the past three years, consistently delivering higher payouts to shareholders.

9 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (2.096) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

10 PBV

The stock's high Price-to-Book Value (P/BV) ratio (33.35x) suggests it's overvalued, potentially making it an expensive investment.

11 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

Novo Nordisk A/S Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Novo Nordisk A/S Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Novo Nordisk A/S Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Novo Nordisk A/S Revenue
Year Revenue Growth
1985 4.158.399.600
1986 4.187.427.750 0.69%
1987 5.027.783.550 16.71%
1988 5.629.806.000 10.69%
1989 7.619.108.250 26.11%
1990 8.331.880.000 8.55%
1991 9.829.419.700 15.24%
1992 10.670.777.000 7.88%
1993 13.145.607.000 18.83%
1994 13.517.840.700 2.75%
1995 13.713.124.800 1.42%
1996 14.903.938.620 7.99%
1997 16.984.033.110 12.25%
1998 17.909.684.240 5.17%
1999 20.944.397.330 14.49%
2000 20.815.014.000 -0.62%
2001 23.717.034.390 12.24%
2002 25.154.110.260 5.71%
2003 26.613.062.700 5.48%
2004 29.233.563.870 8.96%
2005 33.713.685.040 13.29%
2006 38.751.814.800 13%
2007 41.888.774.000 7.49%
2008 45.666.120.400 8.27%
2009 51.078.000.000 10.6%
2010 60.776.000.000 15.96%
2011 66.346.000.000 8.4%
2012 78.026.000.000 14.97%
2013 83.572.000.000 6.64%
2014 88.806.000.000 5.89%
2015 107.927.000.000 17.72%
2016 111.780.000.000 3.45%
2017 111.696.000.000 -0.08%
2018 111.831.000.000 0.12%
2019 122.021.000.000 8.35%
2020 126.946.000.000 3.88%
2021 140.800.000.000 9.84%
2022 176.954.000.000 20.43%
2023 234.924.000.000 24.68%
2023 232.261.000.000 -1.15%
2024 272.240.000.000 14.69%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Novo Nordisk A/S Research and Development Expenses
Year Research and Development Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 2.769.619.590 100%
1998 3.398.509.072 18.5%
1999 3.356.426.540 -1.25%
2000 3.224.522.400 -4.09%
2001 3.959.800.740 18.57%
2002 4.133.370.960 4.2%
2003 4.203.929.700 1.68%
2004 4.384.760.190 4.12%
2005 5.074.703.900 13.6%
2006 6.317.370.800 19.67%
2007 8.550.608.000 26.12%
2008 7.874.022.400 -8.59%
2009 7.864.000.000 -0.13%
2010 9.602.000.000 18.1%
2011 9.628.000.000 0.27%
2012 10.897.000.000 11.65%
2013 11.733.000.000 7.13%
2014 13.762.000.000 14.74%
2015 13.608.000.000 -1.13%
2016 14.563.000.000 6.56%
2017 14.014.000.000 -3.92%
2018 14.805.000.000 5.34%
2019 14.220.000.000 -4.11%
2020 15.462.000.000 8.03%
2021 17.772.000.000 13%
2022 24.047.000.000 26.09%
2023 32.512.000.000 26.04%
2023 32.443.000.000 -0.21%
2024 64.664.000.000 49.83%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Novo Nordisk A/S General and Administrative Expenses
Year General and Administrative Expenses Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 2.764.000.000 100%
2010 3.722.000.000 25.74%
2011 3.245.000.000 -14.7%
2012 3.312.000.000 2.02%
2013 3.508.000.000 5.59%
2014 3.537.000.000 0.82%
2015 3.857.000.000 8.3%
2016 3.962.000.000 2.65%
2017 3.784.000.000 -4.7%
2018 3.916.000.000 3.37%
2019 4.007.000.000 2.27%
2020 3.958.000.000 -1.24%
2021 4.050.000.000 2.27%
2022 4.467.000.000 9.34%
2023 5.024.000.000 11.09%
2023 4.855.000.000 -3.48%
2024 4.628.000.000 -4.9%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Novo Nordisk A/S EBITDA
Year EBITDA Growth
1985 673.196.400
1986 675.510.000 0.34%
1987 708.413.300 4.64%
1988 1.015.977.200 30.27%
1989 1.265.336.250 19.71%
1990 1.185.235.200 -6.76%
1991 1.542.832.150 23.18%
1992 812.288.750 -89.94%
1993 2.264.094.000 64.12%
1994 2.420.806.290 6.47%
1995 2.611.944.600 7.32%
1996 2.153.386.815 -21.29%
1997 2.307.445.740 6.68%
1998 2.092.223.070 -10.29%
1999 4.805.456.500 56.46%
2000 4.908.974.400 2.11%
2001 5.806.036.950 15.45%
2002 6.051.424.950 4.06%
2003 6.007.303.200 -0.73%
2004 8.473.178.640 29.1%
2005 9.285.762.540 8.75%
2006 10.758.742.400 13.69%
2007 10.851.908.000 0.86%
2008 14.480.284.400 25.06%
2009 18.200.000.000 20.44%
2010 21.740.000.000 16.28%
2011 22.394.000.000 2.92%
2012 32.208.000.000 30.47%
2013 35.061.000.000 8.14%
2014 38.094.000.000 7.96%
2015 52.488.000.000 27.42%
2016 51.616.000.000 -1.69%
2017 52.164.000.000 1.05%
2018 51.164.000.000 -1.95%
2019 57.791.000.000 11.47%
2020 60.215.000.000 4.03%
2021 67.556.000.000 10.87%
2022 82.040.000.000 17.65%
2023 131.024.000.000 37.39%
2023 112.940.000.000 -16.01%
2024 137.496.000.000 17.86%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Novo Nordisk A/S Gross Profit
Year Gross Profit Growth
1985 2.085.026.400
1986 893.582.250 -133.33%
1987 2.437.990.350 63.35%
1988 2.913.201.200 16.31%
1989 3.854.154.750 24.41%
1990 4.206.660.800 8.38%
1991 5.034.162.550 16.44%
1992 8.144.214.000 38.19%
1993 6.737.922.000 -20.87%
1994 9.684.441.340 30.43%
1995 9.883.602.800 2.02%
1996 10.736.554.344 7.94%
1997 12.262.328.118 12.44%
1998 13.522.703.264 9.32%
1999 15.894.971.500 14.92%
2000 16.435.438.800 3.29%
2001 17.752.271.250 7.42%
2002 18.529.392.420 4.19%
2003 19.151.235.300 3.25%
2004 21.128.068.500 9.36%
2005 24.547.698.120 13.93%
2006 29.162.746.600 15.83%
2007 32.085.236.000 9.11%
2008 35.534.735.600 9.71%
2009 40.640.000.000 12.56%
2010 49.096.000.000 17.22%
2011 53.757.000.000 8.67%
2012 64.561.000.000 16.73%
2013 69.432.000.000 7.02%
2014 74.244.000.000 6.48%
2015 91.739.000.000 19.07%
2016 94.597.000.000 3.02%
2017 94.064.000.000 -0.57%
2018 94.214.000.000 0.16%
2019 101.933.000.000 7.57%
2020 106.014.000.000 3.85%
2021 117.142.000.000 9.5%
2022 148.506.000.000 21.12%
2023 196.072.000.000 24.26%
2023 196.496.000.000 0.22%
2024 231.144.000.000 14.99%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Novo Nordisk A/S Net Profit
Year Net Profit Growth
1985 607.759.200
1986 521.317.500 -16.58%
1987 480.404.200 -8.52%
1988 637.907.200 24.69%
1989 745.986.750 14.49%
1990 760.121.600 1.86%
1991 930.193.550 18.28%
1992 1.272.690.250 26.91%
1993 1.430.347.500 11.02%
1994 1.431.443.860 0.08%
1995 1.561.735.600 8.34%
1996 1.802.530.706 13.36%
1997 2.219.119.182 18.77%
1998 2.408.763.364 7.87%
1999 2.410.121.260 0.06%
2000 3.088.162.000 21.96%
2001 3.851.198.610 19.81%
2002 4.090.904.820 5.86%
2003 4.872.064.800 16.03%
2004 5.048.785.200 3.5%
2005 5.856.397.420 13.79%
2006 6.452.985.200 9.25%
2007 8.535.266.000 24.4%
2008 9.666.004.400 11.7%
2009 10.768.000.000 10.23%
2010 14.403.000.000 25.24%
2011 17.097.000.000 15.76%
2012 21.432.000.000 20.23%
2013 25.184.000.000 14.9%
2014 26.481.000.000 4.9%
2015 34.860.000.000 24.04%
2016 37.925.000.000 8.08%
2017 38.130.000.000 0.54%
2018 38.628.000.000 1.29%
2019 38.951.000.000 0.83%
2020 42.138.000.000 7.56%
2021 47.757.000.000 11.77%
2022 55.525.000.000 13.99%
2023 89.912.000.000 38.25%
2023 83.683.000.000 -7.44%
2024 80.200.000.000 -4.34%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Novo Nordisk A/S Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1985 0
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 1 0%
1998 1 0%
1999 1 0%
2000 1 0%
2001 1 100%
2002 1 0%
2003 1 0%
2004 1 0%
2005 2 0%
2006 2 50%
2007 3 0%
2008 3 33.33%
2009 4 0%
2010 5 25%
2011 6 33.33%
2012 8 14.29%
2013 9 22.22%
2014 10 10%
2015 14 23.08%
2016 8 -85.71%
2017 8 0%
2018 8 0%
2019 8 12.5%
2020 9 11.11%
2021 10 10%
2022 12 16.67%
2023 20 40%
2023 19 -11.11%
2024 18 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Novo Nordisk A/S Free Cashflow
Year Free Cashflow Growth
1990 332.697.600
1991 -163.803.950 303.11%
1992 -624.113.750 73.75%
1993 -487.201.500 -28.1%
1994 925.512.980 152.64%
1995 1.032.474.600 10.36%
1996 -126.284.372 917.58%
1997 421.776.432 129.94%
1998 1.336.857.298 68.45%
1999 1.700.392.300 21.38%
2000 2.895.653.200 41.28%
2001 375.930.450 -670.26%
2002 927.177.390 59.45%
2003 3.665.874.000 74.71%
2004 4.483.540.770 18.24%
2005 4.803.632.760 6.66%
2006 4.424.419.800 -8.57%
2007 7.568.720.000 41.54%
2008 10.853.526.800 30.26%
2009 12.313.000.000 11.85%
2010 15.782.000.000 21.98%
2011 18.042.000.000 12.53%
2012 18.592.000.000 2.96%
2013 22.298.000.000 16.62%
2014 27.357.000.000 18.49%
2015 31.881.000.000 14.19%
2016 40.047.000.000 20.39%
2017 32.520.000.000 -23.15%
2018 32.206.000.000 -0.97%
2019 35.551.000.000 9.41%
2020 29.870.000.000 -19.02%
2021 47.615.000.000 37.27%
2022 64.134.000.000 25.76%
2023 70.012.000.000 8.4%
2023 30.342.000.000 -130.74%
2024 37.265.000.000 18.58%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Novo Nordisk A/S Operating Cashflow
Year Operating Cashflow Growth
1990 1.504.070.400
1991 1.186.248.100 -26.79%
1992 1.327.888.250 10.67%
1993 1.912.113.000 30.55%
1994 2.662.826.110 28.19%
1995 2.529.923.000 -5.25%
1996 1.921.666.906 -31.65%
1997 3.031.860.456 36.62%
1998 3.475.574.214 12.77%
1999 3.629.967.910 4.25%
2000 5.261.907.200 31.01%
2001 4.310.669.160 -22.07%
2002 4.876.528.410 11.6%
2003 6.178.771.500 21.08%
2004 7.644.519.330 19.17%
2005 8.699.492.400 12.13%
2006 7.741.322.000 -12.38%
2007 9.997.870.000 22.57%
2008 12.896.921.200 22.48%
2009 15.378.000.000 16.13%
2010 19.679.000.000 21.86%
2011 21.374.000.000 7.93%
2012 22.214.000.000 3.78%
2013 25.942.000.000 14.37%
2014 31.692.000.000 18.14%
2015 38.287.000.000 17.23%
2016 48.314.000.000 20.75%
2017 41.168.000.000 -17.36%
2018 44.616.000.000 7.73%
2019 46.782.000.000 4.63%
2020 51.951.000.000 9.95%
2021 55.000.000.000 5.54%
2022 78.887.000.000 30.28%
2023 108.908.000.000 27.57%
2023 40.966.000.000 -165.85%
2024 50.503.000.000 18.88%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Novo Nordisk A/S Capital Expenditure
Year Capital Expenditure Growth
1990 1.171.372.800
1991 1.350.052.050 13.23%
1992 1.952.002.000 30.84%
1993 2.399.314.500 18.64%
1994 1.737.313.130 -38.1%
1995 1.497.448.400 -16.02%
1996 2.047.951.278 26.88%
1997 2.610.084.024 21.54%
1998 2.138.716.916 -22.04%
1999 1.929.575.610 -10.84%
2000 2.366.254.000 18.45%
2001 3.934.738.710 39.86%
2002 3.949.351.020 0.37%
2003 2.512.897.500 -57.16%
2004 3.160.978.560 20.5%
2005 3.895.859.640 18.86%
2006 3.316.902.200 -17.45%
2007 2.429.150.000 -36.55%
2008 2.043.394.400 -18.88%
2009 3.065.000.000 33.33%
2010 3.897.000.000 21.35%
2011 3.332.000.000 -16.96%
2012 3.622.000.000 8.01%
2013 3.644.000.000 0.6%
2014 4.335.000.000 15.94%
2015 6.406.000.000 32.33%
2016 8.267.000.000 22.51%
2017 8.648.000.000 4.41%
2018 12.410.000.000 30.31%
2019 11.231.000.000 -10.5%
2020 22.081.000.000 49.14%
2021 7.385.000.000 -199%
2022 14.753.000.000 49.94%
2023 38.896.000.000 62.07%
2023 10.624.000.000 -266.11%
2024 13.238.000.000 19.75%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Novo Nordisk A/S Equity
Year Equity Growth
1985 4.915.857.600
1986 4.074.353.250 -20.65%
1987 5.165.564.450 21.12%
1988 5.526.008.600 6.52%
1989 6.259.284.750 11.72%
1990 7.028.814.400 10.95%
1991 9.501.811.800 26.03%
1992 10.555.990.250 9.99%
1993 11.954.443.500 11.7%
1994 13.132.919.730 8.97%
1995 14.420.284.000 8.93%
1996 16.023.223.219 10%
1997 18.174.045.186 11.83%
1998 18.035.790.836 -0.77%
1999 18.630.385.200 3.19%
2000 15.745.615.600 -18.32%
2001 20.083.040.040 21.6%
2002 22.896.327.150 12.29%
2003 25.294.530.600 9.48%
2004 26.687.220.030 5.22%
2005 27.592.520.460 3.28%
2006 30.128.999.200 8.42%
2007 32.223.314.000 6.5%
2008 33.058.056.000 2.53%
2009 35.734.000.000 7.49%
2010 36.965.000.000 3.33%
2011 37.448.000.000 1.29%
2012 40.632.000.000 7.84%
2013 42.569.000.000 4.55%
2014 40.294.000.000 -5.65%
2015 46.969.000.000 14.21%
2016 45.269.000.000 -3.76%
2017 49.815.000.000 9.13%
2018 51.839.000.000 3.9%
2019 57.593.000.000 9.99%
2020 63.325.000.000 9.05%
2021 70.746.000.000 10.49%
2022 83.486.000.000 15.26%
2023 92.991.000.000 10.22%
2023 106.561.000.000 12.73%
2024 112.522.000.000 5.3%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Novo Nordisk A/S Assets
Year Assets Growth
1985 7.362.133.200
1986 8.150.175.000 9.67%
1987 8.266.854.000 1.41%
1988 9.226.282.800 10.4%
1989 11.660.255.250 20.87%
1990 12.499.841.600 6.72%
1991 15.272.205.100 18.15%
1992 16.775.801.250 8.96%
1993 19.240.042.500 12.81%
1994 21.129.303.230 8.94%
1995 20.145.170.000 -4.89%
1996 21.046.601.092 4.28%
1997 25.685.910.828 18.06%
1998 27.340.292.154 6.05%
1999 31.043.248.990 11.93%
2000 24.601.020.400 -26.19%
2001 28.829.688.510 14.67%
2002 31.453.254.360 8.34%
2003 34.488.779.100 8.8%
2004 37.695.766.890 8.51%
2005 41.896.251.080 10.03%
2006 44.696.246.000 6.26%
2007 47.795.444.000 6.48%
2008 50.726.463.600 5.78%
2009 54.742.000.000 7.34%
2010 61.402.000.000 10.85%
2011 64.698.000.000 5.09%
2012 65.669.000.000 1.48%
2013 70.337.000.000 6.64%
2014 77.062.000.000 8.73%
2015 91.799.000.000 16.05%
2016 97.539.000.000 5.88%
2017 102.355.000.000 4.71%
2018 110.769.000.000 7.6%
2019 125.612.000.000 11.82%
2020 144.922.000.000 13.32%
2021 194.508.000.000 25.49%
2022 241.257.000.000 19.38%
2023 300.101.000.000 19.61%
2023 314.486.000.000 4.57%
2024 369.383.000.000 14.86%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Novo Nordisk A/S Liabilities
Year Liabilities Growth
1985 2.446.275.600
1986 4.075.821.750 39.98%
1987 3.101.289.550 -31.42%
1988 3.700.274.200 16.19%
1989 5.400.970.500 31.49%
1990 5.471.027.200 1.28%
1991 5.770.393.300 5.19%
1992 6.219.811.000 7.23%
1993 7.285.599.000 14.63%
1994 7.996.383.500 8.89%
1995 5.724.886.000 -39.68%
1996 5.023.377.873 -13.96%
1997 7.511.865.642 33.13%
1998 9.304.501.318 19.27%
1999 12.412.863.790 25.04%
2000 8.855.404.800 -40.17%
2001 8.746.648.470 -1.24%
2002 8.556.927.210 -2.22%
2003 9.194.248.500 6.93%
2004 11.008.546.860 16.48%
2005 14.303.730.620 23.04%
2006 14.567.246.800 1.81%
2007 15.572.130.000 6.45%
2008 17.668.407.600 11.86%
2009 19.008.000.000 7.05%
2010 24.437.000.000 22.22%
2011 27.250.000.000 10.32%
2012 25.037.000.000 -8.84%
2013 27.768.000.000 9.84%
2014 36.768.000.000 24.48%
2015 44.830.000.000 17.98%
2016 52.270.000.000 14.23%
2017 52.540.000.000 0.51%
2018 58.930.000.000 10.84%
2019 68.019.000.000 13.36%
2020 81.597.000.000 16.64%
2021 123.762.000.000 34.07%
2022 157.771.000.000 21.56%
2023 207.110.000.000 23.82%
2023 207.925.000.000 0.39%
2024 256.861.000.000 19.05%

Novo Nordisk A/S Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
57.88
Net Income per Share
20.17
Price to Earning Ratio
39.48x
Price To Sales Ratio
13.77x
POCF Ratio
30.78
PFCF Ratio
53.82
Price to Book Ratio
31.55
EV to Sales
13.79
EV Over EBITDA
27.16
EV to Operating CashFlow
30.85
EV to FreeCashFlow
53.88
Earnings Yield
0.03
FreeCashFlow Yield
0.02
Market Cap
3.553,26 Bil.
Enterprise Value
3.557,50 Bil.
Graham Number
107.02
Graham NetNet
-28.31

Income Statement Metrics

Net Income per Share
20.17
Income Quality
1.28
ROE
0.87
Return On Assets
0.24
Return On Capital Employed
0.63
Net Income per EBT
0.79
EBT Per Ebit
1.01
Ebit per Revenue
0.44
Effective Tax Rate
0.21

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0.17
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.85
Operating Profit Margin
0.44
Pretax Profit Margin
0.44
Net Profit Margin
0.35

Dividends

Dividend Yield
0.01
Dividend Yield %
1.22
Payout Ratio
0.47
Dividend Per Share
0.21

Operating Metrics

Operating Cashflow per Share
25.87
Free CashFlow per Share
14.81
Capex to Operating CashFlow
0.43
Capex to Revenue
0.19
Capex to Depreciation
2.85
Return on Invested Capital
0.52
Return on Tangible Assets
0.29
Days Sales Outstanding
94.03
Days Payables Outstanding
272.12
Days of Inventory on Hand
332.44
Receivables Turnover
3.88
Payables Turnover
1.34
Inventory Turnover
1.1
Capex per Share
11.06

Balance Sheet

Cash per Share
14,06
Book Value per Share
25,24
Tangible Book Value per Share
12.79
Shareholders Equity per Share
25.24
Interest Debt per Share
13.63
Debt to Equity
0.51
Debt to Assets
0.15
Net Debt to EBITDA
0.03
Current Ratio
0.94
Tangible Asset Value
57,02 Bil.
Net Current Asset Value
-79,36 Bil.
Invested Capital
155072000000
Working Capital
-10,41 Bil.
Intangibles to Total Assets
0.15
Average Receivables
64,79 Bil.
Average Payables
21,38 Bil.
Average Inventory
34978000000
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Novo Nordisk A/S Dividends
Year Dividends Growth
1982 0
1983 0 0%
1984 0 0%
1985 0 0%
1986 0 0%
1987 0 0%
1988 0 0%
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 1 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Novo Nordisk A/S Profile

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

CEO
Mr. Lars Fruergaard Jorgensen
Employee
71.880
Address
Novo Allé 1
Bagsvaerd, 2880

Novo Nordisk A/S Executives & BODs

Novo Nordisk A/S Executives & BODs
# Name Age
1 Dr. Martin Holst Lange
Executive Vice President of Development & Member of the Management Board
70
2 Mr. Douglas J. Langa
Executive Vice President of North America Operations & Member of Management Board
70
3 Mr. Karsten Munk Knudsen
Executive Vice President, Chief Financial Officer & Member of the Management Board
70
4 Ms. Camilla Sylvest
Executive Vice President of Commercial Strategy & Corporate Affairs and Member of the Management Board
70
5 Mr. Maziar Mike Doustdar
Executive Vice President of International Operations & Member of the Management Board
70
6 Mr. Ludovic Helfgott
Executive Vice President, Head of Rare Disease & Member of Management Board
70
7 Ms. Tania Sabroe
Executive Vice President of Global People & Organisation and Member of Management Board
70
8 Mr. Lars Fruergaard Jorgensen
President, Chief Executive Officer & Member of Management Board
70
9 Mr. Henrik Ehlers Wulff
Executive Vice President of Product Supply, Quality & IT and Member of the Management Board
70
10 Dr. Marcus Schindler Ph.D.
EVice President of Research & Early Development, Chief Scientific Officer & Member of the Management Board
70

Novo Nordisk A/S Competitors